OpGen (OPGN) could be the COVID-19 winner
What’s up with OpGen?
OpGen (OPGN) opened at $2.31, which means the stock is down 2.60% from yesterday’s closing price of 2.31. Today, the company has a high of $2.35 and a low of $2.21. The company has a market cap of $33.18 million with a 52-week high of $15.20 and a 52-week low of $0.92.
What about the future for OpGen?
The high forecast for OpGen is 5.00 while the low is 1.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. OpGen has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information OPGN seems to be a safe buy.
OpGen, Inc. engages in the development of molecular information products and services for global healthcare settings. It offers guidance to clinicians about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.